Nada Bennani Mechita1, Majdouline Obtel2, Abdelilah Elmarnissi3, Laila Lahlou2, Aziza Lyaghfouri4, Imad Cherkaoui5, Mustapha Mrabet6, Rachid Razine2, Redouane Abouqal7. 1. Laboratory of Public Health, Faculty of Medicine and Pharmacy, Mohamed V University in Rabat, Morocco; Laboratory of Biostatistics, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Mohamed V University in Rabat, Morocco. Electronic address: nadaben7@gmail.com. 2. Laboratory of Public Health, Faculty of Medicine and Pharmacy, Mohamed V University in Rabat, Morocco; Laboratory of Biostatistics, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Mohamed V University in Rabat, Morocco. 3. Directorate of Planning and Financial Resources, Ministry of Health, Rabat, Morocco. 4. Directorate of Population, Ministry of Health, Rabat, Morocco. 5. Directorate of Epidemiology and Disease Control, Ministry of Health, Rabat, Morocco. 6. Laboratory of Public Health, Faculty of Medicine and Pharmacy, Mohamed V University in Rabat, Morocco; Department of Hygiene and Community Medicine, Military Instruction Hospital Mohamed V, Rabat, Morocco. 7. Laboratory of Biostatistics, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Mohamed V University in Rabat, Morocco; Medical Emergency Department, Ibn Sina University Hospital, Rabat, Morocco.
Abstract
AIM: The objective of this study was to analyse the effect of the introduction in 2010 of the pneumococcal conjugate vaccine (PCV) on the reduction in mortality from respiratory causes in children under 5 years in Morocco. METHODS: Child mortality rates from respiratory cause were analysed using an interrupted time series analysis. Mortality rates from congenital and chromosomal causes were also analysed for comparative purposes. RESULTS: In the post-vaccination period, child mortality rates from respiratory causes decreased by 28% (Mortality rate ratio (MRR)=0.72, 95% CI: 0.58-0.83) and by 30% in children under 1 year (MRR=0.70, 95% CI: 0.50-0.98). In children aged between 1 and 5 years, the decrease in the child mortality rate was not statistically significant (MRR=0.99, 95% CI: 0.91-1.08). Mortality rates from congenital and chromosomal causes in the post-vaccination period were stable in children under 5 years (MRR=1.19, 95% CI: 0.97-1.48), in children under 1 year (MRR=1.15, 95% CI: 0.94-1.40) and in children aged between 1 and 5 years (MRR=1.19, 95% CI: 0.97-1.48). CONCLUSION: The decrease in child mortality from respiratory causes in the post-vaccination period provides strong evidence of the effectiveness of PCV.
AIM: The objective of this study was to analyse the effect of the introduction in 2010 of the pneumococcal conjugate vaccine (PCV) on the reduction in mortality from respiratory causes in children under 5 years in Morocco. METHODS:Child mortality rates from respiratory cause were analysed using an interrupted time series analysis. Mortality rates from congenital and chromosomal causes were also analysed for comparative purposes. RESULTS: In the post-vaccination period, child mortality rates from respiratory causes decreased by 28% (Mortality rate ratio (MRR)=0.72, 95% CI: 0.58-0.83) and by 30% in children under 1 year (MRR=0.70, 95% CI: 0.50-0.98). In children aged between 1 and 5 years, the decrease in the child mortality rate was not statistically significant (MRR=0.99, 95% CI: 0.91-1.08). Mortality rates from congenital and chromosomal causes in the post-vaccination period were stable in children under 5 years (MRR=1.19, 95% CI: 0.97-1.48), in children under 1 year (MRR=1.15, 95% CI: 0.94-1.40) and in children aged between 1 and 5 years (MRR=1.19, 95% CI: 0.97-1.48). CONCLUSION: The decrease in child mortality from respiratory causes in the post-vaccination period provides strong evidence of the effectiveness of PCV.
Authors: Carina King; Naor Bar-Zeev; Rob Heyderman; Neil French; Tambosi Phiri; James Beard; Hazzie Mvula; Amelia Crampin; Ellen Heinsbroek; Dan Hungerford; Sonia Lewycka; Jennifer Verani; Cynthia Whitney; Anthony Costello; Charles Mwansambo; Nigel Cunliffe Journal: BMJ Glob Health Date: 2020-09